Christensen MB - Search Results

1

The impact of type 2 diabetes and glycaemic control on mortality and clinical outcomes in hospitalized patients with COVID-19 in the capital region of Denmark.

Kliim-Hansen V, Johansson KS, Gasbjerg LS, Jimenez-Solem E, Petersen TS, Nyeland ME, Winther-Jensen M, Ankarfeldt MZ, Pedersen MG, Ellegaard AM, Knop FK, Christensen MB. Kliim-Hansen V, et al. Among authors: christensen mb. Diabetes Obes Metab. 2024 Jan;26(1):160-168. doi: 10.1111/dom.15302. Epub 2023 Oct 5. Diabetes Obes Metab. 2024. PMID: 37799010

2

Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

Christensen M, Knop FK, Holst JJ, Vilsboll T. Christensen M, et al. IDrugs. 2009 Aug;12(8):503-13. IDrugs. 2009. PMID: 19629885 Review.

3

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

Christensen M, Knop FK. Christensen M, et al. Curr Diab Rep. 2010 Apr;10(2):124-32. doi: 10.1007/s11892-010-0102-x. Curr Diab Rep. 2010. PMID: 20425571 Review.

4

Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.

Christensen M, Knop FK, Vilsbøll T, Aaboe K, Holst JJ, Madsbad S, Krarup T. Christensen M, et al. Regul Pept. 2010 Aug 9;163(1-3):96-101. doi: 10.1016/j.regpep.2010.05.004. Epub 2010 May 24. Regul Pept. 2010. PMID: 20580750

5

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Jimenez-Solem E, Rasmussen MH, Christensen M, Knop FK. Jimenez-Solem E, et al. Curr Opin Mol Ther. 2010 Dec;12(6):790-7. Curr Opin Mol Ther. 2010. PMID: 21154170

6

Lixisenatide for type 2 diabetes mellitus.

Christensen M, Knop FK, Vilsbøll T, Holst JJ. Christensen M, et al. Expert Opin Investig Drugs. 2011 Apr;20(4):549-57. doi: 10.1517/13543784.2011.562191. Epub 2011 Mar 11. Expert Opin Investig Drugs. 2011. PMID: 21391833 Review.

7

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.

Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Christensen M, et al. Diabetes. 2011 Dec;60(12):3103-9. doi: 10.2337/db11-0979. Epub 2011 Oct 7. Diabetes. 2011. PMID: 21984584 Free PMC article. Clinical Trial.

8

The unobtainable placebo: control of independent clinical research by industry?

Christensen M, Knop FK. Christensen M, et al. Lancet. 2012 Jan 7;379(9810):30. doi: 10.1016/S0140-6736(12)60024-5. Lancet. 2012. PMID: 22225670 No abstract available.

9

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Vilsbøll T, et al. BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771. BMJ. 2012. PMID: 22236411 Free PMC article. Review.

10

Therapy for obesity based on gastrointestinal hormones.

Bagger JI, Christensen M, Knop FK, Vilsbøll T. Bagger JI, et al. Rev Diabet Stud. 2011 Fall;8(3):339-47. doi: 10.1900/RDS.2011.8.339. Epub 2011 Nov 10. Rev Diabet Stud. 2011. PMID: 22262071 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters